Soligenix Updates Medical Advisory Board to Advance HyBryte Phase 3 Development for CTCL Treatment

Soligenix Inc. has announced updates to its U.S. Medical Advisory Board for cutaneous T-cell lymphoma to support the ongoing Phase 3 development of HyBryte, the company's synthetic hypericin photodynamic therapy. The board, comprised of leading dermatologic and oncologic experts, will provide strategic guidance as Soligenix advances regulatory and commercialization activities for this innovative treatment approach. President and CEO Christopher J. Schaber emphasized that the addition of new key opinion leaders reinforces the program's clinical depth and the company's commitment to bringing HyBryte to CTCL patients worldwide.

The HyBryte development program represents a significant advancement in the treatment of cutaneous T-cell lymphoma, a rare disease with substantial unmet medical needs. With successful completion of the second Phase 3 study, Soligenix plans to seek regulatory approvals to support potential commercialization worldwide. The company's Specialized BioTherapeutics business segment is focused on developing and moving toward potential commercialization of HyBryte as a novel photodynamic therapy utilizing safe visible light for CTCL treatment. This therapeutic approach offers a promising alternative to existing treatments, potentially providing improved safety and efficacy profiles for patients suffering from this challenging condition.

Beyond the CTCL application, Soligenix is exploring expansion of synthetic hypericin into psoriasis treatment, demonstrating the platform technology's broader potential in dermatological conditions. The company's development pipeline also includes first-in-class innate defense regulator technology with dusquetide for inflammatory diseases, including oral mucositis in head and neck cancer, and applications in Behcet's Disease. These complementary programs highlight Soligenix's strategic focus on addressing rare diseases with limited treatment options, positioning the company as an important player in the specialized biopharmaceutical landscape.

The Medical Advisory Board updates come at a critical juncture as Soligenix prepares for potential regulatory submissions and commercialization planning. The expertise provided by the board members will be instrumental in navigating the complex regulatory landscape and ensuring optimal positioning of HyBryte in the treatment paradigm for cutaneous T-cell lymphoma. For additional information about Soligenix and its development programs, visit https://ibn.fm/SNGX. The company's approach to rare disease treatment represents an important advancement in medical science, potentially offering new hope for patients with limited therapeutic options.